{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:34:37Z","timestamp":1774017277429,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jgar.2022.11.010","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T03:52:02Z","timestamp":1668657122000},"page":"158-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-2623","authenticated-orcid":false,"given":"Roberta","family":"Gagliardini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Cozzi-Lepri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-451X","authenticated-orcid":false,"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-0072","authenticated-orcid":false,"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-1789","authenticated-orcid":false,"given":"Antonella d'Arminio","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.11.010_bib0001","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs. continuing a tenofovir alafenamide-based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with Human Immunodeficiency Virus type 1: phase","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.010_bib0002","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains Human Immunodeficiency Virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.010_bib0003","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.2","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.jgar.2022.11.010_bib0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.11.010_bib0006","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkz009","article-title":"Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: Long-term data from clinical practice","volume":"74","author":"Baldin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.010_bib0007","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1093\/jac\/dkaa319","article-title":"Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy","volume":"75","author":"Calza","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.010_bib0008","article-title":"Real-world experience with dolutegravir-based two-drug regimens","volume":"2020","author":"Ward","year":"2020","journal-title":"AIDS Res Treat"},{"key":"10.1016\/j.jgar.2022.11.010_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12981-021-00352-0","article-title":"Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV","volume":"18","author":"Rolle","year":"2021","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2022.11.010_bib0010","first-page":"69","article-title":"Italian expert panel consensus statements on two-drug antiretroviral regimens to treat na\u00efve and virologically suppressed HIV-1 infected patients","volume":"42","author":"Antinori","year":"2019","journal-title":"New Microbiol"},{"key":"10.1016\/j.jgar.2022.11.010_bib0011","series-title":"Conf Retroviruses Opportunistic IIfections","article-title":"Factors associated with therapeutic failure of 2 Drug-Regimen (DAT'AIDS cohort)","author":"Allavena","year":"2019"},{"key":"10.1016\/j.jgar.2022.11.010_bib0012","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir!lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.010_bib0013","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study","volume":"76","author":"Rial-Crestelo","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.010_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.010_bib0015","unstructured":"Santoro MM, Armenia D, Teyssou E, Santos JR, Charpentier C et al. Impact of M184V on the virological efficacy of switch to 3TC\/DTG in Real Life. Abstr 429 CROI 2021 Virtual, March 6\u201310, 2021 n.d."},{"key":"10.1016\/j.jgar.2022.11.010_bib0016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence","volume":"22","author":"Punekar","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.11.010_bib0017","article-title":"Association of first-line and second-line antiretroviral therapy adherence","volume":"2","author":"Ramadhani","year":"2014","journal-title":"OFID"},{"key":"10.1016\/j.jgar.2022.11.010_bib0018","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1086\/499313","article-title":"Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study","volume":"193","author":"Todd","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.010_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2019.04.009","article-title":"Is the rate of virological failure to cART continuing to decline in recent calendar years?","volume":"116","author":"Rusconi","year":"2019","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jgar.2022.11.010_bib0020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkab367","article-title":"Dolutegravir-based dual maintenance regimens combined with lamivudine\/emtricitabine or rilpivirine: risk of virological failure in a real-life setting","volume":"77","author":"Deschanvres","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.11.010_bib0021","doi-asserted-by":"crossref","first-page":"e23335","DOI":"10.1097\/MD.0000000000023335","article-title":"Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV","volume":"99","author":"dong","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2022.11.010_bib0022","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2022.11.010_bib0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12879-018-3666-8","article-title":"Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice","volume":"19","author":"Borghetti","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.11.010_bib0024","unstructured":"Dovato - SUMMARY OF PRODUCT CHARACTERISTICS. n.d."},{"key":"10.1016\/j.jgar.2022.11.010_bib0025","unstructured":"Center for Drug Evaluation and Research - Labeling DOVATO. n.d."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522002569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522002569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:08Z","timestamp":1761991148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522002569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"alternative-id":["S2213716522002569"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.11.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}